Glimepiride

Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes

Retrieved on: 
Tuesday, July 21, 2020
RTT, Organ systems, Health, Endocrine system, Anti-diabetic drugs, Type 2 diabetes, SGLT2 inhibitor, Glimepiride, Hypoglycemia, Diabetes

THE WOODLANDS, Texas, July 21, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS.

Key Points: 
  • THE WOODLANDS, Texas, July 21, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS.
  • All four Phase 3 sotagliflozin studies met their primary objectives of lowering A1C in patients with type 2 diabetes.
  • Safety results were similar to those in other studies of sotagliflozin in type 2 diabetes, with similar incidences of hypoglycemia on sotagliflozin and placebo.
  • Safety results were similar to those in other studies of sotagliflozin in type 2 diabetes, with less hypoglycemia on sotagliflozin than glimepiride.

Linagliptin and Glimepiride Have Comparable Cardiovascular Safety Effects in Type 2 Diabetes at High Cardiovascular Risk

Retrieved on: 
Tuesday, June 11, 2019
RTT, Organic compounds, Organ systems, Medical specialties, Glimepiride, Sulfonylurea, Anti-diabetic medication, Dipeptidyl peptidase-4 inhibitor, Linagliptin, Cardiovascular disease, Insulin, Diabetes

The study was featured today at "The CAROLINA TrialFirst Results of the Cardiovascular Outcomes Trial Comparing Linagliptin vs. Glimepiride" symposium.

Key Points: 
  • The study was featured today at "The CAROLINA TrialFirst Results of the Cardiovascular Outcomes Trial Comparing Linagliptin vs. Glimepiride" symposium.
  • CVD is a major risk for and the leading cause of death for people living with T2D, and since 2008, the FDA requires diabetes medications to demonstrate cardiovascular (CV) safety.
  • Although linagliptin and glimepiride work differently, they both lower glucose levels by stimulating the body's insulin production.
  • "In CAROLINA, we wanted to test this question using a current-generation sulfonylurea, and we found that glimepiride does not increase cardiovascular risk relative to linagliptin.

China Glimepiride Market Report, 2013-2022 - Focus on the Third-Generation Sulfonylurea Insulin Secretagogue

Retrieved on: 
Tuesday, December 4, 2018
Endocrine system, Medicine, RTT, Endocrinology, Anti-diabetic drugs, Potassium channel blockers, Sulfonylureas, Diabetes, Glimepiride, Anti-diabetic medication, Insulin, Hypoglycemia

Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin.

Key Points: 
  • Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin.
  • For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin.
  • For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.
  • Sales of Glimepiride in China, 2013-2017
    2.3 Sales of Glimepiride by Dosage Form in China, 2013-2017